AMGN

$465.520.11%-0.49

Dopo l'orario di chiusura: 466.80+1.28 +0.27%

Amgen Inc (AMGN)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$466.01

Aprire:

$463.43

Volume 24 ore:

2,348,303

Volume relativo:

0.90

Capitalizzazione di mercato:

$251.68B

Reddito:

$37.30B

Utile/perdita netta:

$7.80B

Rapporto P/E:

32.37

EPS:

$14.38

Flusso di cassa netto:

$8.60B

1W Prestazione:

+4.70%

1M Prestazione:

+15.50%

6M Prestazione:

+41.14%

1Y Prestazione:

+55.99%

Intervallo 1D:

$461.00$469.00

Intervallo di 1 settimana:

$439.57$475.65

Portata 52W:

$288.00$475.65

Profilo aziendale di Amgen Inc (AMGN)

Nome

Amgen Inc

Settore

Healthcare

Industria

Drug Manufacturers - General

Telefono

(805)447-1000

Indirizzo

ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, USA

Dipendente

31,500

@amgen

Prossima data di guadagno

2026-11-03

Ultimi documenti SEC

SEC

Discussioni di AMGN su X

Confronta AMGN con LLY, JNJ, ABBV, MRK, NVS

Azioni	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AMGN Amgen Inc	$251.68B	$38.10B	$8.74B	$10.18B	$14.38
LLY Lilly Eli Co	$1.26T	$86.46B	$27.58B	$10.37B	$27.78
JNJ Johnson Johnson	$651.30B	$99.34B	$16.10B	$20.59B	$8.63
ABBV Abbvie Inc	$510.48B	$64.39B	$6.31B	$18.21B	$2.03
MRK Merck Co Inc	$366.35B	$66.57B	$3.17B	$16.06B	$3.55
NVS Novartis Ag Adr	$304.99B	$54.66B	$13.58B	$16.05B	$7.02

Amgen Inc Azioni (AMGN) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-09-08	Downgrade	BMO Capital Markets	Outperform → Market Perform
2026-08-05	Reiterato	BMO Capital Markets	Outperform
2026-08-05	Reiterato	BofA Securities	Underperform
2026-08-05	Reiterato	Canaccord Genuity	Hold
2026-08-05	Reiterato	Morgan Stanley	Equal-Weight
2026-08-05	Reiterato	Oppenheimer	Outperform
2026-08-05	Reiterato	RBC Capital Mkts	Outperform
2026-08-05	Reiterato	Robert W. Baird	Underperform
2026-08-05	Reiterato	Truist	Hold
2026-08-05	Reiterato	Wells Fargo	Equal Weight
2026-05-05	Downgrade	Erste Group	Buy → Hold
2026-04-21	Iniziato	Canaccord Genuity	Hold
2026-03-10	Iniziato	Jefferies	Hold
2026-02-20	Iniziato	Barclays	Equal Weight
2026-01-20	Downgrade	Bernstein	Outperform → Mkt Perform
2026-01-07	Resumed	UBS	Buy
2025-12-05	Aggiornamento	Erste Group	Hold → Buy
2025-11-24	Resumed	Truist	Hold
2025-11-13	Iniziato	Scotiabank	Sector Outperform
2025-09-03	Resumed	Raymond James	Mkt Perform
2025-05-20	Resumed	Guggenheim	Neutral
2025-04-22	Resumed	Cantor Fitzgerald	Neutral
2024-12-10	Resumed	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Peer Perform
2024-11-14	Iniziato	Citigroup	Neutral
2024-10-17	Iniziato	Bernstein	Outperform
2024-10-14	Downgrade	Truist	Buy → Hold
2024-09-27	Iniziato	Cantor Fitzgerald	Overweight
2024-08-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-05-03	Aggiornamento	Barclays	Underweight → Equal Weight
2024-05-03	Aggiornamento	William Blair	Mkt Perform → Outperform
2024-03-28	Resumed	Raymond James	Mkt Perform
2024-02-07	Downgrade	Leerink Partners	Outperform → Market Perform
2023-12-21	Aggiornamento	Daiwa Securities	Neutral → Buy
2023-12-19	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-12-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-02	Aggiornamento	Truist	Hold → Buy
2023-10-20	Resumed	JP Morgan	Neutral
2023-10-17	Resumed	Morgan Stanley	Equal-Weight
2023-10-11	Resumed	BofA Securities	Neutral
2023-09-06	Iniziato	HSBC Securities	Buy
2023-04-24	Reiterato	Oppenheimer	Outperform
2023-03-13	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-02-13	Reiterato	Truist	Buy
2022-11-18	Iniziato	Credit Suisse	Underperform
2022-10-31	Downgrade	Barclays	Equal Weight → Underweight
2022-10-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-05-23	Iniziato	SVB Leerink	Mkt Perform
2022-02-09	Reiterato	Barclays	Equal Weight
2022-02-09	Reiterato	Jefferies	Buy
2022-02-09	Reiterato	Morgan Stanley	Equal-Weight
2022-02-09	Reiterato	Oppenheimer	Outperform
2022-02-09	Reiterato	Wells Fargo	Equal Weight
2022-01-05	Downgrade	BofA Securities	Buy → Neutral
2021-12-09	Resumed	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Iniziato	BMO Capital Markets	Market Perform
2021-09-23	Downgrade	Daiwa Securities	Outperform → Neutral
2021-09-07	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-12-29	Iniziato	Daiwa Securities	Buy
2020-10-28	Iniziato	UBS	Neutral
2020-10-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2020-10-12	Aggiornamento	Truist	Hold → Buy
2020-10-09	Downgrade	Bernstein	Outperform → Mkt Perform
2020-10-09	Downgrade	Truist	Buy → Hold
2020-10-08	Downgrade	Raymond James	Outperform → Mkt Perform
2020-04-15	Resumed	Guggenheim	Neutral
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-03-30	Aggiornamento	Raymond James	Mkt Perform → Outperform
2020-03-05	Aggiornamento	BofA/Merrill	Neutral → Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-01-31	Downgrade	Robert W. Baird	Neutral → Underperform
2020-01-21	Aggiornamento	Evercore ISI	In-line → Outperform
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-17	Resumed	Morgan Stanley	Overweight
2019-11-12	Iniziato	SunTrust	Buy
2019-11-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2019-10-17	Resumed	BofA/Merrill	Neutral
2019-08-19	Downgrade	Mizuho	Buy → Neutral
2019-05-23	Aggiornamento	Citigroup	Neutral → Buy

Amgen Inc Azioni (AMGN) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	36,751.00	33,424.00	28,190.00	26,323.00	25,979.00
Cost of revenue USD (M)	12,037.00	12,858.00	8,451.00	6,406.00	6,454.00
Gross profit USD (M)	-	-	19,739.00	19,917.00	19,525.00
Operating expenses USD (M)	27,671.00	26,166.00	11,842.00	10,351.00	11,886.00
Operating income USD (M)	9,080.00	7,258.00	7,897.00	9,566.00	7,639.00
Income before tax USD (M)	8,976.00	4,609.00	7,855.00	7,346.00	6,701.00
Income tax expense USD (M)	1,265.00	519.00	1,138.00	794.00	808.00
Net income USD (M)	7,711.00	4,090.00	6,717.00	6,552.00	5,893.00
Basic EPS USD/shares	14.33	7.62	12.56	12.18	10.34
Diluted EPS USD/shares	14.23	7.56	12.49	12.11	10.28
Basic weighted shares shares (M)	538.00	537.00	535.00	538.00	570.00
Diluted weighted shares shares (M)	542.00	541.00	538.00	541.00	573.00
Selling, general and administrative USD (M)	7,050.00	7,096.00	6,179.00	5,414.00	5,368.00

Amgen Inc Azioni (AMGN) insider trading

Khosla RachnaAug 13 '26
SVP, Business Development
Transazione
Option Exercise
Costo
$162.60
#Azioni
1,252
Valore ($)
203,575
#Azioni Totale
7,656
Khosla RachnaAug 13 '26
SVP, Business Development
Transazione
Sale
Costo
$416.43
#Azioni
1,252
Valore ($)
521,365
#Azioni Totale
6,404
Khosla RachnaAug 13 '26
Officer
Transazione
Proposed Sale
Costo
$412.76
#Azioni
1,252
Valore ($)
516,775
#Azioni Totale
0
Khosla RachnaAug 11 '26
Officer
Transazione
Proposed Sale
Costo
$414.21
#Azioni
2,000
Valore ($)
828,420
#Azioni Totale
0
Khosla RachnaAug 11 '26
SVP, Business Development
Transazione
Sale
Costo
$412.57
#Azioni
2,000
Valore ($)
825,134
#Azioni Totale
6,404
Grygiel Nancy A.Aug 06 '26
Officer
Transazione
Proposed Sale
Costo
$447.17
#Azioni
2,670
Valore ($)
1,193,940
#Azioni Totale
0
Miller DerekAug 06 '26
SVP, Human Resources
Transazione
Sale
Costo
$402.54
#Azioni
3,890
Valore ($)
1,565,898
#Azioni Totale
12,462
Miller DerekAug 06 '26
SVP, Human Resources
Transazione
Option Exercise
Costo
$169.56
#Azioni
3,890
Valore ($)
659,574
#Azioni Totale
14,531
Grygiel Nancy A.Aug 06 '26
SVP & CCO
Transazione
Option Exercise
Costo
$177.41
#Azioni
2,970
Valore ($)
526,906
#Azioni Totale
9,310
Grygiel Nancy A.Aug 06 '26
SVP & CCO
Transazione
Sale
Costo
$402.16
#Azioni
2,970
Valore ($)
1,194,415
#Azioni Totale
7,340

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Khosla Rachna	SVP, Business Development	Aug 13 '26	Option Exercise	$162.60	1,252	203,575	7,656
Khosla Rachna	SVP, Business Development	Aug 13 '26	Sale	$416.43	1,252	521,365	6,404
Khosla Rachna	Officer	Aug 13 '26	Proposed Sale	$412.76	1,252	516,775	0
Khosla Rachna	Officer	Aug 11 '26	Proposed Sale	$414.21	2,000	828,420	0
Khosla Rachna	SVP, Business Development	Aug 11 '26	Sale	$412.57	2,000	825,134	6,404
Grygiel Nancy A.	Officer	Aug 06 '26	Proposed Sale	$447.17	2,670	1,193,940	0
Miller Derek	SVP, Human Resources	Aug 06 '26	Sale	$402.54	3,890	1,565,898	12,462
Miller Derek	SVP, Human Resources	Aug 06 '26	Option Exercise	$169.56	3,890	659,574	14,531
Grygiel Nancy A.	SVP & CCO	Aug 06 '26	Option Exercise	$177.41	2,970	526,906	9,310
Grygiel Nancy A.	SVP & CCO	Aug 06 '26	Sale	$402.16	2,970	1,194,415	7,340

Amgen Inc Borsa (AMGN) Ultime notizie

Nov 02, 2026

Amgen Just Gave Its Shareholders Great News - The Motley Fool

Nov 02, 2026

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? - Zacks Investment Research

Nov 02, 2026

Amgen (AMGN) Gets FDA Warning Letter Over Misleading Vectibix Promotion - Yahoo Finance

Nov 02, 2026

38,406 Shares in Amgen Inc. $AMGN Acquired by Vise Technologies Inc. - MarketBeat

Nov 02, 2026

Amgen price soars - Forecast today - 02-11-2026 - Economies.com

Nov 02, 2026

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

Nov 02, 2026

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

Nov 02, 2026

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - TradingView

Nov 02, 2026

Amgen Inc. $AMGN Stock Holdings Raised by MGO One Seven LLC - MarketBeat

Nov 02, 2026

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Zacks Investment Research

Nov 02, 2026

Watch The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic - Bloomberg.com

Nov 02, 2026

Hunt for the Next Ozempic Started With a Trove of Icelandic DNA - Bloomberg.com

Nov 02, 2026

Nov 01, 2026

Amgen (AMGN) reports Q3: everything you need to know ahead of earnings - FinancialContent

Nov 01, 2026

Oct 31, 2026

Looking For Growth, Income, and Stability? This Stock Could Offer All 3 - The Motley Fool

Oct 31, 2026

Oct 30, 2026

Amgen: I Have Clear Doubts About This Company Headed Into Earnings - Earnings Preview - Seeking Alpha

Oct 30, 2026

Amgen stock hits all-time high at 469.02 USD - Investing.com

Oct 30, 2026

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Oct 29, 2026

Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 29, 2026

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.

Oct 29, 2026

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Oct 29, 2026

Oct 28, 2026

Amgen Rises Nearly 100 Spots on TIME's World's Best Companies List - Amgen

Oct 28, 2026

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Oct 28, 2026

Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research

Oct 28, 2026

FDA warns Amgen over cancer drug promotional video - TradingView

Oct 28, 2026

Amgen Announces the Appointment of David Gibbs to Its Board of Directors - Oncodaily

Oct 28, 2026

Amgen (AMGN) Maintains Quarterly Dividend at $2.52 with 2.25% Yi - GuruFocus

Oct 28, 2026

Oct 27, 2026

AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND - Amgen

Oct 27, 2026

Regeneron, Amgen Further Narrow Lawsuit Over Eylea Biosimilars - Bloomberg Law News

Oct 27, 2026

FDA Flags Amgen's Vectibix Promotional Video as Misleading, Rais - GuruFocus

Oct 27, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

Oct 27, 2026

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 - Amgen

Oct 27, 2026

Beyond the DNA We Inherit: A Broader View of Human Genetics - Amgen

Oct 27, 2026

Amgen receives FDA warning letter over Vectibix ad - Seeking Alpha

Oct 27, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - Yahoo Finance

Oct 27, 2026

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

Oct 27, 2026

FDA warns Amgen over cancer drug promotional video - Reuters

Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Oct 27, 2026

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Oct 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Oct 27, 2026

Amgen Stock: A Biotech Bargain Heading Into Q3 Earnings (NASDAQ:AMGN) - Seeking Alpha

Oct 27, 2026

Oct 26, 2026

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS - Amgen

Oct 26, 2026

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

Oct 26, 2026

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data - BioPharma Dive

Oct 26, 2026

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

Oct 26, 2026

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Oct 26, 2026

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer - Benzinga

Oct 26, 2026

Amgen Inc (AMGN)

Profilo aziendale di Amgen Inc (AMGN)

Confronta AMGN con LLY, JNJ, ABBV, MRK, NVS

Amgen Inc Azioni (AMGN) Upgrade e downgrade

Amgen Inc Azioni (AMGN) Dati Finanziari

Amgen Inc Azioni (AMGN) insider trading

Amgen Inc Borsa (AMGN) Ultime notizie

Amgen Just Gave Its Shareholders Great News - The Motley Fool

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? - Zacks Investment Research

Amgen (AMGN) Gets FDA Warning Letter Over Misleading Vectibix Promotion - Yahoo Finance

38,406 Shares in Amgen Inc. $AMGN Acquired by Vise Technologies Inc. - MarketBeat

Amgen price soars - Forecast today - 02-11-2026 - Economies.com

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - Zacks Investment Research

Beat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in Focus - TradingView

Amgen Inc. $AMGN Stock Holdings Raised by MGO One Seven LLC - MarketBeat

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? - Zacks Investment Research

Watch The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic - Bloomberg.com

Hunt for the Next Ozempic Started With a Trove of Icelandic DNA - Bloomberg.com

Amgen (AMGN) reports Q3: everything you need to know ahead of earnings - FinancialContent

Looking For Growth, Income, and Stability? This Stock Could Offer All 3 - The Motley Fool

Amgen: I Have Clear Doubts About This Company Headed Into Earnings - Earnings Preview - Seeking Alpha

Amgen stock hits all-time high at 469.02 USD - Investing.com

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research

Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Amgen Rises Nearly 100 Spots on TIME's World's Best Companies List - Amgen

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research

FDA warns Amgen over cancer drug promotional video - TradingView

Amgen Announces the Appointment of David Gibbs to Its Board of Directors - Oncodaily

Amgen (AMGN) Maintains Quarterly Dividend at $2.52 with 2.25% Yi - GuruFocus

AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND - Amgen

Regeneron, Amgen Further Narrow Lawsuit Over Eylea Biosimilars - Bloomberg Law News

FDA Flags Amgen's Vectibix Promotional Video as Misleading, Rais - GuruFocus

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 - Amgen

Beyond the DNA We Inherit: A Broader View of Human Genetics - Amgen

Amgen receives FDA warning letter over Vectibix ad - Seeking Alpha

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - Yahoo Finance

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

FDA warns Amgen over cancer drug promotional video - Reuters

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Amgen Stock: A Biotech Bargain Heading Into Q3 Earnings (NASDAQ:AMGN) - Seeking Alpha

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS - Amgen

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data - BioPharma Dive

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer - Benzinga

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial - Quartz

Is AMGN Overvalued? DCF Says Worth $204 - GuruFocus

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Simile a AMGN